Sun Pharmaceutical had sought grant of 'emergency authorisation status' to its plant-based drug, ACQH, which is being developed as a potential treatment for dengue.
Sun Pharma said human safety study of AQCH already completed, clinical trials will be conducted across 12 centres on 210 patients. The treatment duration will be 10 days.
The Mumbai-based drug-maker has submitted a proposal to the govt to conduct Phase II clinical trials of the drug to see if it can treat patients suffering from Covid-19.
The latest probe points to challenges for India’s biggest drugmaker after whistle-blower complaints on corporate governance lapses triggered a stock slide last year.
In 2015, billionaire Dilip Shanghvi bought 23% stake for Rs 18 billion, but Suzlon still hasn’t exited India’s debt-restructuring program, missing deadlines since 2017.
On paper, the 21-point plan looks balanced—Palestinian governance, international oversight, reconstruction pledges. But in reality, it is a non-negotiable diktat.
As many as 21 policy reforms are under implementation following Invest Kerala Global Summit, as LDF govt works to change perception that the state is not conducive to businesses.
Amid continued concerns over cross-border terrorism, General Upendra Dwivedi further warned the neighbour that India will not show restraint if there is an Op Sindoor 2.0.
What Munir has achieved with Trump is a return to normal, ironing out the post-Abbottabad crease. The White House picture gives us insight into how Pakistan survives, occasionally thrives and thinks.
COMMENTS